Immunomedics, Inc. (IMMU) Reports IMMU-130 Is Active In Patients With Irinotecan-Refractory Colorectal Cancer
6/2/2014 9:21:27 AM
CHICAGO, June 2, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported 10 of 14 patients (71%) with metastatic colorectal cancer (mCRC) responded to IMMU-130, the Company's novel investigational antibody-drug conjugate (ADC) that comprises an anti-CEACAM5 antibody and SN-38, the active metabolite of irinotecan.
Help employers find you! Check out all the jobs and post your resume.
comments powered by